Balentine LLC Tekla Life Sciences Investors Transaction History

Balentine LLC

$2.2 Billion
Q2 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 15, 2019	SELL	$15.09 - $17.09 $119,708 - $135,574	-7,933 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.54 - $17.47 $4,926 - $5,537	317 Added 4.16%	7,933 $134,000
Q1 2019 May 16, 2019	BUY	$15.5 - $17.9 $3,286 - $3,794	212 Added 2.86%	7,616 $130,000
Q4 2018 Feb 13, 2019	BUY	$13.99 - $20.35 $103,581 - $150,671	7,404 New	7,404 $112,000

Others Institutions Holding HQL

# of Institutions

76

Shares Held

9.04M

Call Options Held

0

Put Options Held

0

Saba Capital Management, L.P. New York, NY

3.43M
Shares

$51.7 Million
0.82% of portfolio
Morgan Stanley New York, NY

490K
Shares

$7.39 Million
0.0% of portfolio
1607 Capital Partners, LLC Richmond, VA

419K
Shares

$6.32 Million
0.53% of portfolio
Karpus Management, Inc. Pittsford, NY

404K
Shares

$6.1 Million
0.18% of portfolio
Allspring Global Investments Holdings, LLC

347K
Shares

$5.23 Million
0.01% of portfolio

About TEKLA LIFE SCIENCES INVESTORS

Ticker HQL
Exchange NYSE
Sector Financial Services
Industry Asset Management
Description
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.